AI model aims to predict ABPA relapse risk
NCT ID NCT07611838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is developing a machine learning model to predict the risk of relapse within one year for people with allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a fungus. Researchers will collect data from 300 patients across multiple hospitals to build and test the model. The goal is to help doctors identify high-risk patients and make better treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a tool that helps doctors predict which ABPA patients are at higher risk of relapse, enabling more personalized monitoring and treatment.
- What could go wrong
- This is an observational study using existing data, not testing a new treatment. The model may not be accurate enough for real-world use, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan, Shandong 250014
RECRUITINGJinan, Shandong, 250014, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a machine learning model beat standard tools in spotting sepsis early?
- Can we predict psoriasis relapse after biologics? a new study digs into the clues.
- AI model aims to predict dangerous lung Flare-Ups in ABPA patients
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- Fungal fingerprints in lungs may predict ABPA Flare-Ups
- AI ultrasound could predict Baby's weight more easily